Taysha Gene Therapies Inc
TSHA5.910USD
+0.200+3.50%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.62BMarket Cap
LossP/E TTM
More Details of Taysha Gene Therapies Inc Company
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
Taysha Gene Therapies Inc Info
Ticker SymbolTSHA
Company nameTaysha Gene Therapies Inc
IPO dateSep 24, 2020
CEONolan (Sean Patrick)
Number of employees73
Security typeOrdinary Share
Fiscal year-endSep 24
Address3000 Pegasus Park Drive
CityDALLAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75247
Phone12146120000
Websitehttps://tayshagtx.com/
Ticker SymbolTSHA
IPO dateSep 24, 2020
CEONolan (Sean Patrick)
Company Executives of Taysha Gene Therapies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Director
Independent Director
2.04M
+2.86%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
307.56K
-15.05%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
297.34K
-66.73%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
105.84K
+115.04%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
President, Head of Research and Development, Director
President, Head of Research and Development, Director
34.23K
--
Dr. Alison Long
Dr. Alison Long
Independent Director
Independent Director
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Director
Independent Director
2.04M
+2.86%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
307.56K
-15.05%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
297.34K
-66.73%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
105.84K
+115.04%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
President, Head of Research and Development, Director
President, Head of Research and Development, Director
34.23K
--
Dr. Alison Long
Dr. Alison Long
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Manning (Paul B.)
9.35%
RTW Investments L.P.
8.89%
RA Capital Management, LP
8.60%
Avoro Capital Advisors LLC
7.92%
Morgan Stanley & Co. LLC
6.97%
Other
58.28%
Shareholders
Shareholders
Proportion
Manning (Paul B.)
9.35%
RTW Investments L.P.
8.89%
RA Capital Management, LP
8.60%
Avoro Capital Advisors LLC
7.92%
Morgan Stanley & Co. LLC
6.97%
Other
58.28%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
28.34%
Investment Advisor
25.96%
Hedge Fund
19.98%
Research Firm
14.04%
Individual Investor
10.48%
Venture Capital
8.83%
Corporation
0.56%
Bank and Trust
0.08%
Pension Fund
0.04%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
289
260.55M
95.12%
+66.39M
2025Q2
275
201.11M
79.83%
-18.39M
2025Q1
280
208.55M
85.47%
-19.89M
2024Q4
274
206.61M
100.79%
-12.49M
2024Q3
266
194.14M
94.73%
-23.74M
2024Q2
250
196.13M
97.09%
+4.27M
2024Q1
251
185.84M
99.33%
-1.52M
2023Q4
229
175.44M
93.86%
-4.17M
2023Q3
220
173.81M
93.01%
+41.64M
2023Q2
198
39.38M
61.40%
-9.23M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Manning (Paul B.)
25.60M
9.38%
+750.00K
+3.02%
May 30, 2025
RTW Investments L.P.
25.02M
9.17%
+6.23M
+33.18%
Jun 30, 2025
RA Capital Management, LP
23.56M
8.63%
+12.68M
+116.65%
Jun 30, 2025
Avoro Capital Advisors LLC
21.70M
7.95%
+1.70M
+8.50%
Jun 30, 2025
Morgan Stanley & Co. LLC
14.66M
5.38%
+21.64K
+0.15%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
12.09M
4.43%
-345.92K
-2.78%
Jun 30, 2025
Fidelity Management & Research Company LLC
15.63M
5.73%
-4.13K
-0.03%
Jun 30, 2025
Goldman Sachs & Company, Inc.
12.53M
4.59%
+12.21M
+3875.21%
Jun 30, 2025
The Vanguard Group, Inc.
10.89M
3.99%
+2.12M
+24.21%
Jun 30, 2025
Invus Public Equities Advisors, LLC
11.01M
4.04%
+4.50M
+69.07%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
1.83%
Virtus LifeSci Biotech Clinical Trials ETF
1.27%
Texas Capital Texas Small Cap Equity Index ETF
0.47%
State Street SPDR S&P Biotech ETF
0.29%
iShares Micro-Cap ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
Vanguard US Momentum Factor ETF
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.13%
Goldman Sachs Innovate Equity ETF
0.1%
View more
iShares Neuroscience and Healthcare ETF
Proportion1.83%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.27%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.47%
State Street SPDR S&P Biotech ETF
Proportion0.29%
iShares Micro-Cap ETF
Proportion0.2%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.18%
Vanguard US Momentum Factor ETF
Proportion0.13%
Invesco Nasdaq Biotechnology ETF
Proportion0.13%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
Goldman Sachs Innovate Equity ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Taysha Gene Therapies Inc?
The top five shareholders of Taysha Gene Therapies Inc are:
Manning (Paul B.) holds 25.60M shares, accounting for 9.38% of the total shares.
RTW Investments L.P. holds 25.02M shares, accounting for 9.17% of the total shares.
RA Capital Management, LP holds 23.56M shares, accounting for 8.63% of the total shares.
Avoro Capital Advisors LLC holds 21.70M shares, accounting for 7.95% of the total shares.
Morgan Stanley & Co. LLC holds 14.66M shares, accounting for 5.38% of the total shares.
Manning (Paul B.) holds 25.60M shares, accounting for 9.38% of the total shares.
RTW Investments L.P. holds 25.02M shares, accounting for 9.17% of the total shares.
RA Capital Management, LP holds 23.56M shares, accounting for 8.63% of the total shares.
Avoro Capital Advisors LLC holds 21.70M shares, accounting for 7.95% of the total shares.
Morgan Stanley & Co. LLC holds 14.66M shares, accounting for 5.38% of the total shares.
What are the top three shareholder types of Taysha Gene Therapies Inc?
The top three shareholder types of Taysha Gene Therapies Inc are:
Manning (Paul B.)
RTW Investments L.P.
RA Capital Management, LP
Manning (Paul B.)
RTW Investments L.P.
RA Capital Management, LP
How many institutions hold shares of Taysha Gene Therapies Inc (TSHA)?
As of 2025Q3, 289 institutions hold shares of Taysha Gene Therapies Inc, with a combined market value of approximately 260.55M, accounting for 95.12% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 15.29%.
What is the biggest source of revenue for Taysha Gene Therapies Inc?
In --, the -- business generated the highest revenue for Taysha Gene Therapies Inc, amounting to -- and accounting for --% of total revenue.
